Deli Huang

List of Publications by Year in Descending Order

44 papers	3,415 citations	20 h-index	50 g-index
50 ext. papers	4,713 ext. citations	17.9 avg, IF	5.31 L-index

#	Paper	IF	Citations
44	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. *Nature Communications*, **2022**, 13, 462	17.4	3
43	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. *Science Translational Medicine*, **2022**, 14, eabi9215	17.5	15
42	Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. *Nature Communications*, **2021**, 12, 5874	17.4	2
41	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes **2021**,		26
40	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses **2021**,		3
39	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants **2021**,		6
38	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *Nature Communications*, **2021**, 12, 2938	17.4	110
37	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. *Science*, **2021**, 373, 818-823	33.3	148
36	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. *Cell Host and Microbe*, **2021**, 29, 806-818.e6	23.4	24
35	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. *Cell Reports*, **2021**, 35, 109109	10.6	7
34	Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. *Clinical Chemistry*, **2021**, 67, 404-414	5.5	32
33	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants **2021**,		26
32	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science*, **2021**, 371, 823-829	33.3	157
31	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection **2021**,		3
30	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. *journal of applied laboratory medicine, The*, **2021**, 6, 1109-1122	2	10
29	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. *Science Translational Medicine*, **2021**, 13, eabj5413	17.5	18
28	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science*, **2020**, 369, 956-963	33.3	906

27	Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science*, **2020**, 369, 731-736	33.3	376
26	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. *PLoS Pathogens*, **2020**, 16, e1009089	7.6	33
25	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model **2020**,		35
24	Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein **2020**,		18
23	Structural basis of a public antibody response to SARS-CoV-2 **2020**,		14
22	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate **2020**,		8
21	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody **2020**,		2
20	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection **2020**,		40
19	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 **2020**,		11
18	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. *Science*, **2020**, 370, 1089-1094	33.3	153
17	Structural basis of a shared antibody response to SARS-CoV-2. *Science*, **2020**, 369, 1119-1123	33.3	338
16	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. *Nature Communications*, **2020**, 11, 5850	17.4	17
15	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. *PLoS Pathogens*, **2020**, 16, e1008665	7.6	25
14	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 22920-22931	11.5	20
13	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
12	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
11	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
10	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		

9	Reprogramming the antigen specificity of B cells using genome-editing technologies. *ELife*, **2019**, 8,	8.9	30
8	PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. *Nature Immunology*, **2018**, 19, 942-953	19.1	56
7	HIV-1 vaccine design through minimizing envelope metastability. *Science Advances*, **2018**, 4, eaau6769	14.3	43
6	Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. *Cell Research*, **2014**, 24, 105-21	24.7	500
5	Regulator of G-protein signaling 19 (RGS19) and its partner G□nhibiting activity polypeptide 3 (GNAI3) are required for zVAD-induced autophagy and cell death in L929 cells. *PLoS ONE*, **2014**, 9, e94634	3.7	9
4	Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling. *Journal of Biological Chemistry*, **2013**, 288, 16247-16261	5.4	177
3	Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2		7
2	In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice		1
1	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques		4